@article{61251baa52624b5fac16f86077ec2870,
title = "Heat shock protein 105 as an immunotherapeutic target for patients with cervical cancer",
abstract = "Background/Aim: Heat shock protein 105 (HSP105) is overexpressed in various cancers, but not in normal tissues. We investigated the expression levels of HSP105 in cervical cancer and the efficacy of immunotherapy targeting HSP105. Materials and Methods: Previously, we established human leukocyte antigen-A∗02:01 (HLA-A2) restricted HSP105 peptide-specific cytotoxic T lymphocyte (CTL) clones from a colorectal cancer patient vaccinated with an HSP105 peptide. Herein, we evaluated the expression of HSP105 in cervical cancer and cervical intraepithelial neoplasia. Moreover, we tested the effectiveness of an HLAA2-restricted HSP105 peptide-specific CTL clone against cervical cancer cell lines. Results: HSP105 was expressed in 95% (19/20) of examined cervical cancer tissues. Moreover, the HSP105 peptide-specific CTL clone recognized HSP105- and HLA-A∗02:01-positive cervical cancer cell lines and also showed that cytotoxicity against the cervical cancer cell lines depends on HSP105 peptide and HLA class I restricted manners. Conclusion: HSP105 could be an effective target for immunotherapy in patients with cervical cancer.",
keywords = "Cancer germline antigen, Cancer immunotherapy, Cervical cancer, Cytotoxic T lymphocyte clone, Heat shock protein 105",
author = "Kazuto Nosaka and Shiro Suzuki and Toshiaki Yoshikawa and Manami Shimomura and Kazuhisa Kitami and Kosuke Yoshida and Masato Yoshihara and Fumitaka Kikkawa and Tetsuya Nakatsura and Hiroaki Kajiyama",
note = "Funding Information: The co-author, TN is the inventor of the peptide vaccine patents. TN received fundamental research funding from Takeda Pharmaceutical Co., Ltd. and MEDINET Co., Ltd. The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The remaining Authors report no conflicts of interest. Funding Information: This study was supported in part by the National Cancer Center Research and Development Fund (25-7 and 28-A-8), Japan Agency for Medical Research and Development (AMED, grant no. JP 16ck0106109 h0003), and by Health and Labor Science Research Grants for Research for Promotion of Cancer Control Programs from the Ministry of Health, Labor, and Welfare, Japan. Publisher Copyright: {\textcopyright} 2021 International Institute of Anticancer Research. All rights reserved.",
year = "2021",
month = oct,
doi = "10.21873/anticanres.15289",
language = "English",
volume = "41",
pages = "4741--4751",
journal = "Anticancer research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",
}
